8-K: Calidi Biotherapeutics Closes $6.1 Million Public Offering

Calidi Biotherapeutics has successfully closed a public offering, raising approximately $6.1 million through the sale of common stock and warrants.

Summary

• Calidi Biotherapeutics closed a public offering on April 18, 2024, raising approximately $6.1 million before deducting fees and expenses.
• The offering included 13,232,500 Common Stock Units and 1,965,000 Pre-Funded Warrant Units, each sold at $0.40 per unit.
• Each Common Stock Unit contains one share of common stock and multiple warrants (Series A, B, and C) to purchase additional shares.
• Each Pre-Funded Warrant Unit includes a pre-funded warrant exercisable at $0.001 per share, along with the same Series A, B, and C warrants as the Common Stock Units.
• The company intends to use the net proceeds for working capital, general corporate purposes, pre-clinical and clinical trials, and debt repayment.
• The Series A warrants expire five years from issuance, Series B warrants expire in twelve months, and Series C warrants expire in four months.
• The exercise price of the warrants is $0.60 per share, subject to adjustment upon a reverse stock split.
• A reverse stock split will reduce the exercise price to the lesser of the current price or 90% of the lowest VWAP for the five trading days after the split.
• The company will hold a shareholder meeting to approve a reverse stock split on or before the 75th day after the offering closing.
• Ladenburg Thalmann & Co. Inc. acted as the placement agent and received an 8% cash fee, a 1% management fee, and up to $125,000 for legal and other expenses.
• The placement agent also received warrants to purchase 759,875 shares at $0.66 per share, exercisable for five years.

Sentiment

Score: 7

Explanation: The document indicates a successful capital raise, which is positive. However, the use of warrants and the need for a reverse stock split introduce some uncertainty and potential dilution, which tempers the overall positive sentiment.

Positives

• The company successfully raised $6.1 million in a public offering, providing capital for operations and development.
• The offering included pre-funded warrants, which provide immediate capital to the company.
• The company has a clear plan for the use of proceeds, including clinical trials and debt repayment.
• The warrants included in the offering provide potential future capital if exercised.

Negatives

• The offering involved the issuance of a large number of warrants, which could dilute existing shareholders.
• The exercise price of the warrants is subject to adjustment upon a reverse stock split, which could be dilutive.
• The company incurred significant fees and expenses related to the offering, including an 8% cash fee to the placement agent.
• The company is required to hold a shareholder meeting to approve a reverse stock split, which may not be favored by all shareholders.

Risks

• The company may not be able to raise sufficient capital to support its current and anticipated clinical trials.
• Early results of clinical trials may not predict final results.
• The company may not receive FDA approval for its therapeutic candidates.
• The reverse stock split could negatively impact the share price.
• The large number of warrants issued could lead to future dilution.

Future Outlook

The company intends to use the net proceeds from the offering for working capital, general corporate purposes, pre-clinical and clinical trials, and debt repayment. They also plan to hold a shareholder meeting to approve a reverse stock split.

Management Comments

• The company announced the closing of its public offering in a press release.
• The company's board of directors has determined the record date for the shareholder meeting to approve the reverse stock split.

Industry Context

This capital raise is typical for a clinical-stage biotechnology company needing funds to advance its research and development. The use of warrants is a common method to attract investors in such offerings. The company is operating in the competitive immuno-oncology space.

Comparison to Industry Standards

• The offering structure, including common stock and warrants, is a standard approach for biotech companies seeking capital.
• The placement agent fees are within the typical range for similar offerings.
• The use of pre-funded warrants is a common method to provide immediate capital to the company.
• The planned reverse stock split is a common strategy for companies seeking to maintain listing compliance or improve their stock price.

Related Party Transactions

• A convertible promissory note with an investor was amended, and the proceeds from the sale of securities to that investor were used to pay off the note.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution from the issuance of warrants and the reverse stock split.
• Employees will benefit from the company's increased financial stability.
• Customers may benefit from the company's ability to advance its clinical trials.
• Creditors will benefit from the company's debt repayment.

Next Steps

• The company will hold a shareholder meeting to approve a reverse stock split.
• The company will use the proceeds from the offering for working capital, clinical trials, and debt repayment.
• The company will continue to develop its therapeutic candidates.

Key Dates

Keywords

public offering, warrants, common stock, capital raise, biotechnology, clinical trials, reverse stock split, immunotherapy, placement agent, pre-funded warrants